Provided by Tiger Trade Technology Pte. Ltd.

Compass Therapeutics, Inc.

2.05
-0.1300-5.96%
Post-market: 2.060.0100+0.49%18:04 EDT
Volume:2.54M
Turnover:5.28M
Market Cap:369.18M
PE:-5.08
High:2.17
Open:2.17
Low:2.04
Close:2.18
52wk High:6.88
52wk Low:1.61
Shares:180.09M
Float Shares:132.00M
Volume Ratio:1.00
T/O Rate:1.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4039
EPS(LYR):-0.4216
ROE:-56.66%
ROA:-33.03%
PB:2.22
PE(LYR):-4.86

Loading ...

Compass Therapeutics to Participate in Upcoming June Investor Events

GlobeNewswire
·
May 28

Compass Therapeutics reports Phase 1 CTX-8371 data showing 33% ORR at top doses

Reuters
·
May 22

Compass Therapeutics to Participate in Upcoming May Investor Events

GlobeNewswire
·
May 12

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH), Tenax Therapeutics (TENX) and Compass Therapeutics (CMPX)

TIPRANKS
·
May 10

Compass Therapeutics Inc. reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 06

Guggenheim Remains a Buy on Compass Therapeutics (CMPX)

TIPRANKS
·
May 06

Compass Therapeutics Inc. : Leerink Partners Cuts Target Price to $4 From $11

THOMSON REUTERS
·
May 06

Compass Therapeutics: Buy Rating Reiterated as Clinical Progress Strengthens Approval Odds; $6 Price Target Maintained

TIPRANKS
·
May 06

H.C. Wainwright Keeps Their Buy Rating on Compass Therapeutics (CMPX)

TIPRANKS
·
May 05

Compass Therapeutics Q1 EPS $(0.10), Inline

Benzinga Earnings
·
May 05

Compass Therapeutics Q1 net loss widens on higher R&D, G&A costs

Reuters
·
May 05

Press Release: Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update

Dow Jones
·
May 05

Compass Therapeutics announces annual shareholder meeting webcast

Reuters
·
Apr 29

Compass Therapeutics Price Target Maintained With a $10.00/Share by Citizens

Dow Jones
·
Apr 28

Compass Therapeutics announces annual shareholder meeting webcast

Reuters
·
Apr 28

Compass Therapeutics publishes 2025 annual report

Reuters
·
Apr 28

Compass Therapeutics price target lowered to $6 from $12 at Stifel

TIPRANKS
·
Apr 28

Compass Therapeutics selloff ‘an over-reaction,’ says Jefferies

TIPRANKS
·
Apr 28

Leerink says Compass data supports path forward for tovecimig in 2L BTC

TIPRANKS
·
Apr 28

This Biotech Stock Is Down 61%. How a Cancer Trial Was Ruined by Its Own Design. -- Barrons.com

Dow Jones
·
Apr 28